[HTML][HTML] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
T John, A Taylor, H Wang, C Eichinger, C Freeman… - Cancer …, 2022 - Elsevier
… clinical understanding of uncommon EGFR mutations, but is the first to systematically
categorise and document both response to EGFR-TKIs and survival in this patient … EGFR-mutated …
categorise and document both response to EGFR-TKIs and survival in this patient … EGFR-mutated …
[HTML][HTML] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
… In conclusion, uncommon EGFR mutations may be associated with a poor outcome and the
data challenge the use of first-generation TKI in such patients, however first-line TKI is more …
data challenge the use of first-generation TKI in such patients, however first-line TKI is more …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
… uncommon EGFR mutations. Moving forward, it will be important to include uncommon EGFR
mutations … , as this will help optimize patient outcomes according to their precise genotype. …
mutations … , as this will help optimize patient outcomes according to their precise genotype. …
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
… According to the reviewed data on relative incidence and clinical outcomes, we were …
uncommon EGFR mutations) and overall similar responses and survival outcomes with any EGFR …
uncommon EGFR mutations) and overall similar responses and survival outcomes with any EGFR …
Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non–small-cell …
T Patil, R Mushtaq, S Marsh, C Azelby, M Pujara… - Clinical lung cancer, 2020 - Elsevier
… post hoc analysis of uncommon EGFR mutations in the LUX-… was to assess clinical outcomes
of patients with a-EGFR and … first treated with agents in clinical trials, and we acknowledge …
of patients with a-EGFR and … first treated with agents in clinical trials, and we acknowledge …
[HTML][HTML] Treatment outcome of atypical EGFR mutations in the German national network genomic medicine lung cancer (nNGM)
M Janning, J Süptitz, C Albers-Leischner, P Delpy… - Annals of oncology, 2022 - Elsevier
… Clinical outcome data of patients with very rare point and compound … with chemotherapy
and rare EGFR mutations were categorized into 3 groups. Group 1 contained point mutations or …
and rare EGFR mutations were categorized into 3 groups. Group 1 contained point mutations or …
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
S Yang, S Mao, X Li, C Zhao, Q Liu, X Yu, Y Wang… - Lung Cancer, 2020 - Elsevier
… aimed to investigate the incidence of acquired T790M mutation and their outcome to
subsequent osimertinib in patients of advanced NSCLC harboring uncommon EGFR mutations. …
subsequent osimertinib in patients of advanced NSCLC harboring uncommon EGFR mutations. …
[HTML][HTML] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
… in patients with advanced NSCLC harboring EGFR exon 20 insertion (exon20ins) mutations
… clinical outcomes of EGFR exon20ins compared with common EGFR (cEGFR) mutations. …
… clinical outcomes of EGFR exon20ins compared with common EGFR (cEGFR) mutations. …
[HTML][HTML] UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-LiNe setting (UNICORN)
… these uncommon mutations. Aside from exon 20 insertions, the most prevalent uncommon
EGFR mutations (… Our results further support the use of first-line osimertinib for patients with …
EGFR mutations (… Our results further support the use of first-line osimertinib for patients with …
[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases
JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
… the most comprehensive analysis of clinical outcomes of EGFR TKI treatment in patients
with NSCLC tumors harboring uncommon EGFR mutations. Results in both TKI-naive and TKI-…
with NSCLC tumors harboring uncommon EGFR mutations. Results in both TKI-naive and TKI-…
相关搜索
- rare egfr mutations clinical consequence
- cell lung cancer uncommon egfr mutations
- tyrosine kinase inhibitors uncommon egfr mutations
- treatment outcomes uncommon egfr mutations
- caucasian patients uncommon egfr mutations
- lung adenocarcinoma patients uncommon egfr mutations
- efficacy of osimertinib uncommon egfr mutations
- lower incidence uncommon egfr mutations
- concurrent genetic alterations uncommon egfr mutations
- post hoc analysis uncommon egfr mutations
- systematic literature review uncommon egfr mutations
- cohort study uncommon egfr mutations
- clinical features uncommon egfr mutations
- rare egfr mutations distinct epidemiology
- retrospective french cohort uncommon egfr mutations
- different generations uncommon egfr mutations